NEFL and myeloid sarcoma: ,37 Serum levels of neurofilament light chains (NfL, released into the CSF following axonal damage and neuronal death) are highly correlated with CSF NfL measurements in matched samples, and longitudinal serum NfL measurements can be used to predict MS disease activity/progression, including new and enlarging T2 lesions and brain volume loss in individual patients.34